Donanemab Found to Slow Cognitive, Functional Decline in Early Alzheimer’s

Donanemab Found to Slow Cognitive, Functional Decline in Early Alzheimer’s
Donanemab (LY3002813), Eli Lilly’s experimental antibody-based immunotherapy, slowed cognitive and functional decline in patients at the earlier stages of Alzheimer’s disease, according to data from a Phase 2 trial. Findings from this trial, called TRAILBLAZER-ALZ (NCT03367403), also showed donanemab had a favorable safety profile, which was consistent with observations from previous clinical trials. “We are extremely pleased about these positive findings for donanemab as a potential therapy for people living with Alzheimer's disease, the only leading cause of death without a treatment that slows disease progression,” Mark Mintun, MD, vice president of pain and neurodegeneration at Eli Lilly, said in a press release. "We look forward to discussing the TRAILBLAZER-ALZ study data and next steps with global regulators," Mintun said. Donanemab is an antibody — a protein that helps fight off infections — that is designed to recognize and bind to a form of the beta-amyloid protein that has already clumped together in plaques in people with Alzheimer's. By doing so, donanemab is expected to trigger an immune response against these harmful plaques and help the body eliminate them. This, in turn, is expected to slow Alzheimer’s progression. “This unique mechanism and antibody for clearing plaques, discovered at Lilly, has the potential to provide high levels of durable amyloid plaque clearance after limited duration dosing,” said Daniel Skovronsky, MD, PhD, chief scientific officer and president of Lilly Research Laboratories. TRAILBLAZER-ALZ is an ongoing Phase 2 trial that's assessing the safety, tolerability, and efficacy of donanemab in patients with early symptomatic Alzheimer’s. A total of 272 older adults, ages 60–85, with early
Subscribe or to access all post and page content.